Literature DB >> 10456920

Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade.

A B Maksymowych1, M Reinhard, C J Malizio, M C Goodnough, E A Johnson, L L Simpson.   

Abstract

Clostridium botulinum serotype A produces a neurotoxin composed of a 100-kDa heavy chain and a 50-kDa light chain linked by a disulfide bond. This neurotoxin is part of a ca. 900-kDa complex, formed by noncovalent association with a single nontoxin, nonhemagglutinin subunit and a family of hemagglutinating proteins. Previous work has suggested, although never conclusively demonstrated, that neurotoxin alone cannot survive passage through the stomach and/or cannot be absorbed from the gut without the involvement of auxiliary proteins in the complex. Therefore, this study compared the relative absorption and toxicity of three preparations of neurotoxin in an in vivo mouse model. Equimolar amounts of serotype A complex with hemagglutinins, complex without hemagglutinins, and purified neurotoxin were surgically introduced into the stomach or into the small intestine. In some experiments, movement of neurotoxin from the site of administration was restricted by ligation of the pylorus. Comparison of relative toxicities demonstrated that at adequate doses, complex with hemagglutinins, complex without hemagglutinins, and pure neurotoxin can be absorbed from the stomach. The potency of neurotoxin in complex was greater than that of pure neurotoxin, but the magnitude of this difference diminished as the dosage of neurotoxin increased. Qualitatively similar results were obtained when complex with hemagglutinins, complex without hemagglutinins, and pure neurotoxin were placed directly into the intestine. This work establishes that pure botulinum neurotoxin serotype A is toxic when administered orally. This means that pure neurotoxin does not require hemagglutinins or other auxiliary proteins for absorption from the gastrointestinal system into the general circulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456920      PMCID: PMC96798     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

Review 1.  Botulinum and tetanus neurotoxins: emerging tools for the study of membrane fusion.

Authors:  R Jahn; P I Hanson; H Otto; G Ahnert-Hilger
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1995

Review 2.  The mechanism of action of tetanus and botulinum neurotoxins.

Authors:  C Montecucco; G Schiavo; O Rossetto
Journal:  Arch Toxicol Suppl       Date:  1996

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Botulism.

Authors:  A B Sanders; S Seifert; M Kobernick
Journal:  J Fam Pract       Date:  1983-05       Impact factor: 0.493

5.  Oral toxicities of Clostridium botulinum type C and D toxins of different molecular sizes.

Authors:  I Ohishi; G Sakaguchi
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

6.  Induction of an immune response by oral administration of recombinant botulinum toxin.

Authors:  N Kiyatkin; A B Maksymowych; L L Simpson
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

7.  The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin.

Authors:  Yukako Fujinaga; Kaoru Inoue; Sadahiro Watanabe; Kenji Yokota; Yoshikazu Hirai; Eiko Nagamachi; Keiji Oguma
Journal:  Microbiology (Reading)       Date:  1997-12       Impact factor: 2.777

8.  Oral toxicities of Clostridium botulinum toxins in response to molecular size.

Authors:  I Ohishi; S Sugii; G Sakaguchi
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

9.  Oral toxicities of Clostridium botulinum type A and B toxins from different strains.

Authors:  I Ohishi
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

10.  Molecular composition of Clostridium botulinum type A progenitor toxins.

Authors:  K Inoue; Y Fujinaga; T Watanabe; T Ohyama; K Takeshi; K Moriishi; H Nakajima; K Inoue; K Oguma
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

View more
  21 in total

Review 1.  Endoscopic treatment of gastroparesis.

Authors:  Thomas R McCarty; Tarun Rustagi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 2.  Botulinum Toxin as a Treatment for Refractory Gastroparesis: a Literature Review.

Authors:  Ashley Thomas; Bruno de Souza Ribeiro; Miguel Malespin; Silvio W de Melo
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

3.  Structural biology. How a neurotoxin survives.

Authors:  Michael Adler
Journal:  Science       Date:  2012-02-24       Impact factor: 47.728

4.  Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route.

Authors:  Fetweh H Al-Saleem; Denise M Ancharski; Suresh G Joshi; M Elias; Ajay Singh; Zidoon Nasser; Lance L Simpson
Journal:  Infect Immun       Date:  2012-09-10       Impact factor: 3.441

Review 5.  Botulinum neurotoxins: genetic, structural and mechanistic insights.

Authors:  Ornella Rossetto; Marco Pirazzini; Cesare Montecucco
Journal:  Nat Rev Microbiol       Date:  2014-06-30       Impact factor: 60.633

6.  Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study.

Authors:  Leonel Rodriguez; Rachel Rosen; Michael Manfredi; Samuel Nurko
Journal:  Gastrointest Endosc       Date:  2012-02       Impact factor: 9.427

7.  Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.

Authors:  Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

8.  Differentiation of the gene clusters encoding botulinum neurotoxin type A complexes in Clostridium botulinum type A, Ab, and A(B) strains.

Authors:  Giovanna Franciosa; Francesca Floridi; Antonella Maugliani; Paolo Aureli
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

Review 9.  Interaction of botulinum toxin with the epithelial barrier.

Authors:  Yukako Fujinaga
Journal:  J Biomed Biotechnol       Date:  2010-02-14

10.  Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex.

Authors:  Ellen R Goldman; George P Anderson; Jerry Conway; Laura J Sherwood; Melissa Fech; BaoHan Vo; Jinny L Liu; Andrew Hayhurst
Journal:  Anal Chem       Date:  2008-10-24       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.